← Back to Screener
Catalyst Pharmaceutical Inc. (CPRX)
Price$25.89
Favorite Metrics
Price vs S&P 500 (26W)22.79%
Price vs S&P 500 (4W)7.51%
Market Capitalization$3.16B
P/E Ratio (Annual)14.75x
All Metrics
P/CF (Annual)15.15x
Book Value / Share (Quarterly)$7.79
P/TBV (Annual)3.49x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)40.10%
Cash Flow / Share (Quarterly)$1.70
Price vs S&P 500 (YTD)8.11%
Gross Margin (TTM)85.19%
Net Profit Margin (TTM)36.39%
EPS (TTM)$1.68
10-Day Avg Trading Volume1.24M
EPS Excl Extra (TTM)$1.68
Revenue Growth (5Y)37.67%
EPS (Annual)$1.68
ROI (Annual)22.46%
Gross Margin (Annual)85.19%
Net Profit Margin (5Y Avg)30.90%
Cash / Share (Quarterly)$5.79
P/E Basic Excl Extra (TTM)14.75x
Revenue Growth QoQ (YoY)7.61%
EPS Growth (5Y)18.99%
P/E Normalized (Annual)14.75x
ROA (Last FY)19.41%
Revenue Growth TTM (YoY)19.78%
EBITD / Share (TTM)$2.52
ROE (5Y Avg)22.03%
Operating Margin (TTM)43.77%
Cash Flow / Share (Annual)$1.70
P/B Ratio3.31x
P/B Ratio (Quarterly)3.01x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)4.16x
Net Interest Coverage (TTM)-91.00x
ROA (TTM)21.24%
EPS Growth QoQ (YoY)-6.93%
EV / EBITDA (TTM)7.64x
EPS Incl Extra (Annual)$1.68
Current Ratio (Annual)6.08x
Quick Ratio (Quarterly)5.70x
3-Month Avg Trading Volume1.24M
52-Week Price Return13.38%
EV / Free Cash Flow (Annual)11.76x
P/E Incl Extra (TTM)14.75x
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$6.71
P/S Ratio (Annual)5.37x
Asset Turnover (Annual)0.53x
52-Week High$26.58
Operating Margin (5Y Avg)38.00%
EPS Excl Extra (Annual)$1.68
Tangible BV CAGR (5Y)27.04%
26-Week Price Return26.78%
Quick Ratio (Annual)5.70x
13-Week Price Return11.33%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.08x
Enterprise Value$2,452.616
Revenue / Share Growth (5Y)32.78%
Asset Turnover (TTM)0.58x
Book Value / Share Growth (5Y)36.66%
Revenue / Employee (Annual)$3
Inventory Turnover (Annual)3.08x
Pretax Margin (Annual)48.14%
Cash / Share (Annual)$5.79
3-Month Return Std Dev35.98%
Gross Margin (5Y Avg)85.31%
Net Income / Employee (TTM)$1
EBITDA CAGR (5Y)47.80%
EBITDA Interim CAGR (5Y)56.38%
ROE (Last FY)22.46%
Net Interest Coverage (Annual)-17.00x
EPS Basic Excl Extra (Annual)$1.68
P/FCF (TTM)15.16x
Receivables Turnover (TTM)6.14x
EV / Free Cash Flow (TTM)11.76x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$1.68
Receivables Turnover (Annual)6.14x
ROI (TTM)24.32%
P/S Ratio (TTM)5.37x
Pretax Margin (5Y Avg)40.43%
Revenue / Share (Annual)$4.63
Tangible BV / Share (Annual)$6.71
Forward P/E13.77x
Free OCF CAGR (5Y)35.90%
Price vs S&P 500 (52W)-16.45%
P/E Ratio (TTM)14.75x
EPS Growth TTM (YoY)28.29%
Year-to-Date Return10.75%
5-Day Price Return0.98%
EPS Normalized (Annual)$1.68
ROA (5Y Avg)18.52%
Net Profit Margin (Annual)36.39%
Month-to-Date Return4.40%
Cash Flow / Share (TTM)$0.77
EBITD / Share (Annual)$2.33
EPS Growth (3Y)31.19%
Operating Margin (Annual)43.77%
P/CF (TTM)15.15x
ROI (5Y Avg)22.03%
P/E Excl Extra (TTM)14.75x
EPS Basic Excl Extra (TTM)$1.68
P/TBV (Quarterly)3.49x
P/B Ratio (Annual)3.01x
Inventory Turnover (TTM)3.05x
Pretax Margin (TTM)48.14%
Book Value / Share (Annual)$7.79
Price vs S&P 500 (13W)10.64%
Net Margin Growth (5Y)-10.39%
Beta0.69x
P/FCF (Annual)15.16x
Revenue / Share (TTM)$4.62
ROE (TTM)24.32%
52-Week Low$19.05
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.43
4.43
4.43
4.43
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CPRXCatalyst Pharmaceutical Inc. | 5.37x | 19.78% | 85.19% | 18.99% | $25.89 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases. The company commercializes three FDA-approved drugs: FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). It pursues growth through acquiring accretive assets, including clinical-stage candidates with established proof of concept.